Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes
Metadatos
Mostrar el registro completo del ítemAutor
de Araújo Farias, Virgínea; Tovar Gálvez, María Isabel; García Morales, María Del Rosario; O´Valle, Francisco; Expósito Hernández, José; Oliver, Francisco Javier; Ruiz De Almodóvar Rivera, José MarianoEditorial
Frontiers Media
Materia
experimental radiotherapy cell loss mesenchymal cells
Fecha
2020-01-08Referencia bibliográfica
de Araújo Farias, V. et. al. Front. Oncol. 9:1381. [https://doi.org/10.3389/fonc.2019.01381]
Patrocinador
Spanish Ministry of Economy and Competitiveness, MINECO: SAF201240011-C02-02 and SAF2015-70520-R to JR; CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico—Brasil to VF; Project of Excellence from the Andalusian Regional Government P12CTS-383 to FO; Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01, SAF2015- 70520-R, RTICC RD12/0036/0026, and CIBER Cáncer ISCIII CB16/12/00421 to FO, VF, and JRResumen
In this paper, we summarize published articles and experiences related to the attempt
to improve radiotherapy outcomes and, thus, to personalize the radiation treatment
according to the individual characteristics of each patient. The evolution of ideas and
the study of successively published data have led us to envisage new biophysical
models for the interpretation of tumor and healthy normal tissue response to radiation.
In the development of the model, we have shown that when mesenchymal stem cells
(MSCs) and radiotherapy are administered simultaneously in experimental radiotherapy
on xenotumors implanted in a murine model, the results of the treatment show the
existence of a synergic mechanism that is able to enhance the local and systemic
actions of the radiation both on the treated tumor and on its possible metastasis. We are
convinced that, due to the physical hallmarks that characterize the neoplastic tissues, the
physical–chemical tropism of MSCs, and the widespread functions of macromolecules,
proteins, and exosomes released from activated MSCs, the combination of radiotherapy
plus MSCs used intratumorally has the effect of counteracting the pro-tumorigenic and
pro-metastatic signals that contribute to the growth, spread, and resistance of the tumor
cells. Therefore, we have concluded that MSCs are appropriate for therapeutic use in a
clinical trial for rectal cancer combined with radiotherapy, which we are going to start in
the near future.